TY - CHAP
T1 - The History of Cellular Therapies
AU - Crees, Zachary D.
AU - Ghobadi, Armin
N1 - Funding Information:
Disclosures AG reports participation in advisory board meetings of Kite, Amgen, BMS, Atara, and Wugen. AG has received research funding from Kite and Amgen.
Publisher Copyright:
© 2022, Springer Nature Switzerland AG.
PY - 2022
Y1 - 2022
N2 - The approval of multiple CAR-T cell and T cell engaging products for lymphoma, leukemia and multiple myeloma in recent years, in addition to hundreds of active clinical trials in cancer using these platforms, marks the start of a new era in gene and cellular therapy for cancer. However, these remarkable achievements in medicine are built upon thousands of years of advancement in the understanding of cancer and immunity with rapid acceleration in the last few decades. In this chapter, we will broadly review historical aspects of gene and cellular therapy development, focusing on major milestones.
AB - The approval of multiple CAR-T cell and T cell engaging products for lymphoma, leukemia and multiple myeloma in recent years, in addition to hundreds of active clinical trials in cancer using these platforms, marks the start of a new era in gene and cellular therapy for cancer. However, these remarkable achievements in medicine are built upon thousands of years of advancement in the understanding of cancer and immunity with rapid acceleration in the last few decades. In this chapter, we will broadly review historical aspects of gene and cellular therapy development, focusing on major milestones.
KW - Allogeneic hematopoietic cell transplantation
KW - Chimeric antigen receptor T-cells (CAR-T)
KW - Donor lymphocyte infusions (DLI)
KW - Dual-targeting immune cell engaging therapies
KW - Gene and cellular therapy history
KW - Hippocrates
KW - Ilya Metchnikoff
KW - Mohammed ibn Zakariya al-Razi
KW - Natural killer (NK) cells
KW - Paul Ehrlich
KW - Pillars of cancer care
KW - Rudolph Virchow
KW - T-cell receptor engineered T-cells (TCR-T)
KW - Tumor infiltrating lymphocytes (TILs)
KW - Viral cytotoxic T-lymphocytes (viral CTLs)
KW - William Coley
UR - http://www.scopus.com/inward/record.url?scp=85122459242&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-87849-8_1
DO - 10.1007/978-3-030-87849-8_1
M3 - Chapter
AN - SCOPUS:85122459242
T3 - Cancer Drug Discovery and Development
SP - 3
EP - 11
BT - Cancer Drug Discovery and Development
PB - Humana Press Inc.
ER -